China's Leading Vaccine Developer Sees Sales Slashed Due To Popular Backlash Against Series Of Scandals
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Pummeled by a de facto nationwide public boycott of domestically produced inoculations following a series of faulty vaccine releases by other firms that have in some cases led to fatalities, China's leading vaccine maker, Sinovac Biotech, reported sales revenues for 2010 that were just half of original projections
You may also be interested in...
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.
China NT Pharma's Hong Kong IPO Could Trigger Consolidation In Distribution Sector
HONG KONG - China's largest vaccine promotion and sales services provider is expected to go public on the Hong Kong Stock Exchange April 20, which will likely lead to consolidation in China's distribution sector